Literature DB >> 7588299

Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3).

P Angelloz-Nicoud1, M Binoux.   

Abstract

PC-3 cells, whose growth is androgen-independent, were shown to be capable of slow proliferation in serum-free medium and in the absence of added growth factor for 7 days. They secreted insulin-like growth factor (IGF)-II but no detectable IGF-I. This IGF-II, although produced in small amounts, plays a role in their proliferation because growth could be inhibited dose dependently by up to 80% in the presence of monoclonal antibodies directed against IGFs or the type 1 IGF receptor. PC-3 cells also secreted IGF binding proteins (IGFBPs) -2, -3, -4, and -6. Immunoblot analysis revealed selective proteolysis of IGFBP-3, yielding fragments of the same molecular size as those generated from IGFBP-3 in vivo. With the addition to the culture medium of a serine protease inhibitor, 4-(2-aminoethyl)-benzenesulfonyl fluoride (Pefabloc-SC), at concentrations < 0.2 mM that were nontoxic to the cells, cell proliferation was dose dependently inhibited up to 80% and, at the same time, proteolysis of the IGFBP-3 secreted by the cells was depressed. Urokinase activity detected in the conditioned media was depressed by Pefabloc, suggesting that the urokinase-type plasminogen activator was involved in the proteolysis of IGFBP-3. In addition, 0.01-5 micrograms/ml plasminogen induced a dose-dependent increase in both proliferation and the proportions of proteolysed IGFBP-3 in the media. The stimulation of proliferation was totally blocked in the presence of anti-type 1 IGF receptor antibody. Recombinant human IGF-II (5-200 ng/ml) added to cell-free medium conditioned by 48 h of culture dose dependently stimulated PC-3 cell proliferation. At concentrations < or = 100 ng/ml, its mitogenic action was potentiated when medium had been conditioned by cells cultured in the presence of plasminogen but inhibited when medium had been conditioned by cells cultured in the presence of Pefabloc. We conclude from these results 1) that IGF-II is involved in the autocrine control of PC-3 cell proliferation via the type 1 IGF receptor; and 2) that this proliferation is directly dependent on IGF-II bioavailability that itself is modulated by the limited IGFBP-3 proteolysis induced, at least in part, by urokinase-type plasminogen activator and plasmin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588299     DOI: 10.1210/endo.136.12.7588299

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  21 in total

Review 1.  Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases.

Authors:  S E Nunn; T B Gibson; R Rajah; P Cohen
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

Review 2.  Insulin-Like growth factor I: implications in aging.

Authors:  E Arvat; F Broglio; E Ghigo
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

3.  Inhibition of gene expression by anti-sense C-5 propyne oligonucleotides detected by a reporter enzyme.

Authors:  Y Hamel; J Lacoste; C Frayssinet; A Sarasin; T Garestier; J C François; C Hélène
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

Review 4.  Growth hormone and prostate cancer: guilty by association?

Authors:  A Grimberg; P Cohen
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

5.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Authors:  Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

6.  HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells.

Authors:  Rusha Thomas; Myoung H Kim
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

7.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

8.  Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator.

Authors:  Youli Hu; David González-Martínez; Soo-Hyun Kim; Pierre Marc Gilles Bouloux
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

9.  Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-alpha.

Authors:  Giovanna Zappala; Cem Elbi; Joanna Edwards; Julie Gorenstein; Matthew M Rechler; Nisan Bhattacharyya
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

10.  Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3.

Authors:  V Hwa; Y Oh; R G Rosenfeld
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.